Hub : Traits :

LDL Cholesterol

499 significantly associated models · 154 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	24871730	26855401	7	2	2.3e-12	1.9e-10	2.9e-01	97	LDLRAP1 TMEM50A
2	1	54527647	56375280	2	1	6.3e-13	1.9e-28	3.3e-22	23	USP24
3	1	61510619	63844736	3	1	6.1e-18	2.6e-18	1.0e+00	100	DOCK7
4	1	92277843	93942442	1	1	4.9e-08	1.5e-07	2.4e-01	95	EVI5
5	1	108654479	111016796	18	8	3.9e-172	9.7e-171	1.0e+00	100	AMIGO1 GSTM1 PSRC1 RP5-1065J22.8 SORT1 STXBP3 TMEM167B
6	2	20062043	21958745	2	2	6.2e-114	4.5e-114	1.0e+00	100	APOB HS1BP3
7	2	43302571	44735953	3	2	1.1e-14	1.7e-47	1.6e-31	35	ABCG5 DYNC2LI1
8	3	11900101	13321852	2	1	2.4e-08	2.2e-07	6.7e-02	88	MKRN2
9	5	73626450	75704085	9	1	1.7e-41	5.1e-45	5.7e-06	90	HMGCR
10	6	33856903	35362848	1	1	3.6e-08	4.7e-07	4.2e-01	98	C6orf106
11	6	115569351	117264735	3	1	2.2e-09	2.9e-09	1.0e+00	100	FRK
12	6	160293151	161336020	2	2	6.4e-08	1.7e-17	1.2e-12	30	LPA SLC22A1
13	7	21336058	22188630	1	1	9.4e-10	6.9e-10	3.4e-02	88	DNAH11
14	7	43885849	45318389	3	4	8.0e-09	1.0e-09	NaN	NaN	DDX56 NPC1L1 TMED4
15	9	135629944	137034272	3	1	6.2e-30	2.3e-21	2.1e-03	90	ABO
16	11	17923676	19345331	2	1	5.2e-08	2.9e-07	8.9e-01	100	SPTY2D1
17	11	60549966	62605067	9	1	1.1e-21	1.2e-21	1.0e+00	100	TMEM258
18	11	115953897	117800682	4	4	4.8e-16	1.5e-14	2.1e-02	91	BUD13 PAFAH1B2 PCSK7 ZNF259
19	11	125134725	126914307	3	2	2.0e-11	1.2e-15	1.7e-05	71	DCPS ST3GAL4
20	12	111193499	113517494	7	1	1.5e-09	1.5e-09	7.8e-03	81	ALDH2
21	12	120722064	122167693	3	1	3.8e-13	3.3e-15	1.9e-03	84	HNF1A
22	13	32275990	33700374	1	1	1.5e-07	7.5e-08	1.4e-01	93	N4BP2L1
23	14	24179343	25582885	1	1	3.8e-08	4.9e-11	2.1e-04	68	NYNRIN
24	16	56330832	57810318	2	1	2.3e-12	1.6e-12	1.0e+00	100	CETP
25	16	71349498	72845749	5	2	3.6e-23	1.8e-22	1.0e+00	100	HP HPR
26	17	26279731	27684579	1	1	1.5e-07	5.3e-05	6.4e-01	99	SDF2
27	17	44788310	46474610	5	1	1.3e-11	3.9e-09	4.2e-02	88	EFCAB13
28	19	9982334	12191233	12	10	3.6e-56	4.3e-117	NaN	NaN	CARM1 DOCK6 KANK2 SMARCA4 SPC24
29	19	18333894	20451172	7	1	5.0e-20	6.7e-22	2.9e-03	90	ATP13A1
30	19	44190626	46547330	16	23	1.2e-84	8.7e-147	NaN	NaN	APOC1 APOE BCAM BLOC1S3 CEACAM16 CEACAM19 CTB-179K24.3 GEMIN7 KLC3 PVR PVRL2 TOMM40 ZNF229 ZNF285
31	19	48525507	49955222	4	1	5.0e-08	7.6e-08	1.0e+00	100	RASIP1
32	20	39270768	40683594	4	1	1.2e-19	3.4e-19	1.0e+00	100	ZHX3

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
High cholesterol (Self-reported)	27.45	47	35	77.8	0.97	2.1e-34	ABCG5 ABO AMIGO1 APOB APOC1 ATP13A1 BCAM BUD13 CARM1 CEACAM16 CEACAM19 CETP DDX56 DNAH11 DOCK7 EFCAB13 GSTM1 HMGCR HNF1A HP HPR HS1BP3 KANK2 LDLRAP1 MKRN2 N4BP2L1 NPC1L1 NYNRIN PAFAH1B2 PCSK7 PSRC1 PVR PVRL2 RASIP1 RP5-1065J22.8 SLC22A1 SMARCA4 SORT1 SPC24 TMED4 TMEM258 TOMM40 USP24 ZHX3 ZNF229 ZNF259 ZNF285
Alzheimer’s Disease (including proxy)	23.41	12	12	26.7	0.53	4.4e-02	APOC1 APOE BCAM CEACAM16 CEACAM19 GEMIN7 KLC3 PVR PVRL2 TOMM40 ZNF229 ZNF285
Triglycerides	17.62	14	12	26.7	0.42	1.3e-01	APOB APOC1 APOE ATP13A1 BUD13 CETP DOCK7 HPR HS1BP3 PAFAH1B2 PCSK7 PVRL2 TMEM258 ZNF259
HDL Cholesterol	17.14	13	9	20.0	-0.46	9.9e-02	APOB APOC1 BUD13 C6orf106 CARM1 CETP HS1BP3 PSRC1 PVRL2 SORT1 TMEM258 TOMM40 ZNF259
Medication: Cholesterol lowering	16.01	28	18	40.0	0.97	4.8e-19	ABCG5 ABO APOB ATP13A1 BCAM BUD13 CEACAM16 CETP DOCK7 DYNC2LI1 GSTM1 HMGCR HNF1A HPR KANK2 NPC1L1 PAFAH1B2 PSRC1 PVRL2 RASIP1 RP5-1065J22.8 SMARCA4 SORT1 SPC24 TOMM40 ZHX3 ZNF229 ZNF259
Cholesterol lowering medication	13.87	28	16	35.6	0.96	7.2e-18	ABCG5 ABO APOB BCAM BUD13 DDX56 DOCK7 HMGCR HNF1A HPR KANK2 N4BP2L1 NPC1L1 PAFAH1B2 PCSK7 PSRC1 PVRL2 RASIP1 SMARCA4 SORT1 SPC24 TMED4 TMEM167B TOMM40 ZHX3 ZNF229 ZNF259 ZNF285
Medication: Simvastatin	13.18	25	16	35.6	0.97	9.4e-18	ABCG5 ABO APOB ATP13A1 BCAM BUD13 CETP DOCK7 GEMIN7 GSTM1 HMGCR HPR NPC1L1 PAFAH1B2 PSRC1 PVRL2 RASIP1 RP5-1065J22.8 SMARCA4 SORT1 SPC24 TMEM258 TOMM40 ZHX3 ZNF259
Medication: Atorvastatin	11.63	21	11	24.4	0.94	1.2e-11	ABO APOB ATP13A1 BCAM BUD13 CARM1 DOCK7 EFCAB13 HMGCR KANK2 PAFAH1B2 PSRC1 PVRL2 RASIP1 SMARCA4 SORT1 SPC24 TOMM40 ZNF229 ZNF259 ZNF285
Alzheimer’s Disease (in mother)	11.18	12	11	24.4	0.56	4.5e-02	APOC1 APOE BCAM CEACAM16 CEACAM19 GEMIN7 KLC3 PVR PVRL2 TOMM40 ZNF229 ZNF285
Alzheimer’s Disease (in father)	6.11	8	5	11.1	0.46	2.6e-01	APOC1 APOE CEACAM19 GEMIN7 PVRL2 TOMM40 ZNF229 ZNF285
Medication for cholesterol, blood pressure or diabetes	5.88	13	6	13.3	-0.93	2.1e-06	APOB BUD13 CETP HMGCR HPR NPC1L1 PAFAH1B2 PSRC1 RASIP1 SORT1 SPC24 TOMM40 ZNF259
Cardiovascular Disease	5.43	27	17	37.8	0.89	2.5e-11	ALDH2 APOB APOE BCAM BUD13 DDX56 DOCK7 EFCAB13 FRK HMGCR HNF1A HPR MKRN2 NPC1L1 PAFAH1B2 PCSK7 PSRC1 PVRL2 RASIP1 SMARCA4 SORT1 SPC24 TMED4 TOMM40 ZNF229 ZNF259 ZNF285
Coronary Artery Disease (CAD)	4.89	4	1	2.2	0.63	2.5e-01	ALDH2 BUD13 PSRC1 ZNF259
Illnesses of father: Heart disease	3.82	5	2	4.4	0.98	6.4e-04	NPC1L1 PSRC1 SORT1 SPC24 ST3GAL4
Angina (self-reported)	3.49	4	2	4.4	0.99	7.0e-04	ABCG5 PSRC1 SORT1 SPC24
Medication for cholesterol	3.39	7	1	2.2	-0.93	7.0e-04	ALDH2 DOCK7 HMGCR PSRC1 PVRL2 RASIP1 SORT1
Angina	3.36	4	2	4.4	0.99	4.4e-04	ABCG5 PSRC1 SORT1 SPC24
Blood Red Count	3.25	20	11	24.4	-0.34	1.4e-01	ABCG5 ABO ALDH2 AMIGO1 ATP13A1 C6orf106 DDX56 EFCAB13 HNF1A HP HPR HS1BP3 KLC3 MKRN2 PCSK7 PVRL2 SDF2 TMED4 TMEM258 ZHX3
Heart attack/myocardial infarction (self-reported)	3.08	3	2	4.4	1.00	4.1e-03	PSRC1 SORT1 SPC24
Heart attack	3.07	3	2	4.4	1.00	4.1e-03	PSRC1 SORT1 SPC24
Medication: Aspirin	3.01	2	2	4.4	0.00	1.0e+00	PSRC1 SORT1
Blood Eosinophil Count	2.87	15	10	22.2	-0.18	5.0e-01	ABO ALDH2 APOC1 APOE BCAM BUD13 CARM1 DCPS HNF1A PAFAH1B2 PVRL2 SMARCA4 TMEM258 TOMM40 ZNF259
Medication: Aspirin	2.82	2	2	4.4	0.00	1.0e+00	PSRC1 SORT1
Blood Platelet Count	2.69	31	28	62.2	-0.51	1.4e-03	ABO ALDH2 APOC1 ATP13A1 BLOC1S3 BUD13 C6orf106 CARM1 CTB-179K24.3 DDX56 DOCK7 EVI5 GEMIN7 GSTM1 HMGCR HNF1A HP HPR KLC3 LDLRAP1 PAFAH1B2 PCSK7 PVR RASIP1 TMED4 TMEM258 TMEM50A TOMM40 ZHX3 ZNF259 ZNF285
Hypothyroidism (self reported)	2.52	4	3	6.7	0.23	7.1e-01	ALDH2 DDX56 RASIP1 TMEM258
Medication: Levothyroxine sodium	2.33	2	2	4.4	0.00	1.0e+00	ALDH2 TMEM258
Hypothyroidism/myxoedema (self-reported)	2.23	2	2	4.4	0.00	1.0e+00	ALDH2 TMEM258
Heart disease (mother)	2.18	1	0	0.0	0.00	1.0e+00	ALDH2
Number of self-reported non-cancer illnesses	2.17	2	0	0.0	0.00	1.0e+00	ALDH2 RASIP1
Number of treatments/medications taken	2.14	4	1	2.2	0.74	2.6e-01	ALDH2 PSRC1 SORT1 TMEM258
Blood White Count	2.13	16	9	20.0	-0.35	1.5e-01	ABO ALDH2 APOC1 APOE ATP13A1 CARM1 CETP EVI5 NYNRIN PAFAH1B2 PVR PVRL2 SMARCA4 ST3GAL4 STXBP3 TMEM258
Blood clot in the leg (DVT)	2.11	1	1	2.2	0.00	1.0e+00	ABO
Medication: Atenolol	2.04	1	0	0.0	0.00	1.0e+00	ALDH2
Deep venous thrombosis (DVT) (self-reported)	2.00	1	1	2.2	0.00	1.0e+00	ABO
Father's age at death	1.91	2	0	0.0	0.00	1.0e+00	PSRC1 SORT1
Hip circumference	1.85	8	4	8.9	-0.36	3.4e-01	ALDH2 C6orf106 CARM1 GSTM1 HMGCR HPR RASIP1 SMARCA4
Arm predicted mass (left)	1.80	8	4	8.9	-0.53	1.4e-01	ALDH2 C6orf106 HMGCR PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1
Trunk predicted mass	1.78	8	6	13.3	-0.53	1.4e-01	ALDH2 C6orf106 HMGCR PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1
Trunk fat-free mass	1.77	8	6	13.3	-0.53	1.4e-01	ALDH2 C6orf106 HMGCR PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1
Basal metabolic rate	1.75	9	5	11.1	-0.46	2.1e-01	ALDH2 ATP13A1 C6orf106 HMGCR PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1
Weight	1.74	7	3	6.7	-0.42	3.5e-01	ALDH2 C6orf106 CARM1 GSTM1 HMGCR HPR SMARCA4
Arm fat-free mass (left)	1.74	8	4	8.9	-0.51	1.6e-01	ALDH2 C6orf106 HMGCR PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1
Arm fat-free mass (right)	1.73	9	4	8.9	-0.52	1.2e-01	ALDH2 C6orf106 HMGCR LPA PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1
Whole body fat-free mass	1.73	10	5	11.1	-0.49	1.2e-01	ALDH2 ATP13A1 C6orf106 HMGCR LPA PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1
Arm predicted mass (right)	1.72	9	3	6.7	-0.51	1.3e-01	ALDH2 C6orf106 HMGCR LPA PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1
Whole body water mass	1.71	10	5	11.1	-0.49	1.3e-01	ALDH2 ATP13A1 C6orf106 HMGCR LPA PSRC1 RASIP1 SMARCA4 SORT1 SPTY2D1
Standing height	1.68	19	13	28.9	-0.44	4.8e-02	ABCG5 ALDH2 AMIGO1 ATP13A1 C6orf106 DCPS EFCAB13 EVI5 FRK KANK2 MKRN2 NYNRIN PSRC1 RASIP1 SMARCA4 SORT1 SPC24 SPTY2D1 TMEM258
Pulse rate, automated reading	1.68	4	2	4.4	-0.09	9.1e-01	C6orf106 KANK2 SORT1 TMEM258
Height	1.67	28	20	44.4	-0.43	1.4e-02	ABCG5 ABO ALDH2 AMIGO1 APOC1 APOE ATP13A1 C6orf106 DCPS EFCAB13 EVI5 FRK GEMIN7 KANK2 MKRN2 NYNRIN PSRC1 RASIP1 SLC22A1 SMARCA4 SORT1 SPC24 SPTY2D1 ST3GAL4 TMEM258 TMEM50A ZNF229 ZNF259
Leg fat-free mass (left)	1.64	7	3	6.7	-0.45	3.1e-01	ALDH2 ATP13A1 C6orf106 CARM1 HMGCR SMARCA4 SPTY2D1
Leg fat-free mass (right)	1.64	6	3	6.7	-0.42	4.1e-01	ALDH2 ATP13A1 C6orf106 HMGCR SMARCA4 SPTY2D1
Leg predicted mass (left)	1.63	7	3	6.7	-0.45	3.1e-01	ALDH2 ATP13A1 C6orf106 CARM1 HMGCR SMARCA4 SPTY2D1
Leg predicted mass (right)	1.63	6	3	6.7	-0.42	4.0e-01	ALDH2 ATP13A1 C6orf106 HMGCR SMARCA4 SPTY2D1
Pulse rate	1.61	1	1	2.2	0.00	1.0e+00	TMEM258
Myopia	1.61	3	0	0.0	0.00	1.0e+00	C6orf106 KANK2 TMEM258
Waist Hip Ratio (WHR)	1.60	10	4	8.9	0.59	4.2e-02	APOC1 APOE ATP13A1 C6orf106 CARM1 KANK2 MKRN2 RASIP1 SMARCA4 ZHX3
Vascular/heart problems diagnosed by doctor	1.59	4	1	2.2	0.50	5.0e-01	ALDH2 EVI5 NPC1L1 RASIP1
Respiratory disease	1.58	3	1	2.2	0.00	1.0e+00	ABO BLOC1S3 TMEM258
Forced expiratory volume in 1-second (FEV1), predicted	1.57	1	1	2.2	0.00	1.0e+00	C6orf106
Asthma	1.56	3	1	2.2	0.00	1.0e+00	BLOC1S3 SMARCA4 TMEM258
Asthma (self-reported)	1.56	3	1	2.2	0.00	1.0e+00	ABO BLOC1S3 TMEM258
Comparative height size at age 10	1.55	14	5	11.1	-0.41	1.2e-01	ALDH2 ATP13A1 C6orf106 DCPS EVI5 HNF1A KANK2 MKRN2 NYNRIN PSRC1 RASIP1 SORT1 SPC24 SPTY2D1
Diabetes (mother)	1.52	2	0	0.0	0.00	1.0e+00	ATP13A1 PVRL2
Supplements: Fish oil (including cod liver oil)	1.51	1	0	0.0	0.00	1.0e+00	TMEM258
Medication: Blood pressure	1.50	2	0	0.0	0.00	1.0e+00	ALDH2 NPC1L1
Fasting Glucose	1.49	1	1	2.2	0.00	1.0e+00	TMEM258
Primary Biliary Cirrhosis	1.48	1	0	0.0	0.00	1.0e+00	ALDH2
Bipolar Disorder (2018)	1.46	1	0	0.0	0.00	1.0e+00	TMEM258
HbA1C	1.46	1	0	0.0	0.00	1.0e+00	ABO
Chronic bronchitis/emphysema (mother)	1.46	1	0	0.0	0.00	1.0e+00	BCAM
Allergy	1.45	4	1	2.2	-0.75	2.5e-01	ABO BLOC1S3 C6orf106 TMEM258
Birth weight of first child	1.45	3	1	2.2	0.00	1.0e+00	ALDH2 ATP13A1 HP
Trunk fat mass	1.44	6	3	6.7	-0.48	3.3e-01	C6orf106 FRK GSTM1 HMGCR HPR PVRL2
Systolic Blood Pressure	1.43	8	3	6.7	0.08	8.6e-01	ALDH2 APOC1 APOE PAFAH1B2 PCSK7 RASIP1 SMARCA4 TOMM40
High blood pressure	1.43	3	1	2.2	0.00	1.0e+00	ALDH2 NPC1L1 RASIP1
Leg fat mass (right)	1.43	5	2	4.4	-0.36	5.6e-01	ALDH2 C6orf106 GSTM1 HMGCR HPR
Osteoarthritis (self-reported)	1.43	1	0	0.0	0.00	1.0e+00	SMARCA4
Whole body fat mass	1.41	5	3	6.7	-0.48	4.1e-01	C6orf106 GSTM1 HMGCR HPR PVRL2
Arm fat mass (left)	1.41	4	2	4.4	-0.84	1.6e-01	C6orf106 GSTM1 HMGCR HPR
Leg fat mass (left)	1.41	4	2	4.4	-0.86	1.4e-01	C6orf106 GSTM1 HMGCR HPR
Birth weight	1.40	2	1	2.2	0.00	1.0e+00	ALDH2 RASIP1
Arm fat mass (right)	1.38	4	2	4.4	-0.82	1.8e-01	C6orf106 GSTM1 HMGCR HPR
Hypertension (Self-reported)	1.35	2	2	4.4	0.00	1.0e+00	ALDH2 RASIP1
Diastolic blood pressure, automated reading	1.35	2	1	2.2	0.00	1.0e+00	ABO ALDH2
Medication: Metformin	1.32	1	0	0.0	0.00	1.0e+00	APOC1
Alcohol intake versus 10 years previously	1.32	2	0	0.0	0.00	1.0e+00	AMIGO1 RASIP1
Seen a psychiatrist for nerves, anxiety, tension or depression	1.32	1	0	0.0	0.00	1.0e+00	TMEM258
Medication: Blood pressure	1.32	2	1	2.2	0.00	1.0e+00	ALDH2 RASIP1
Waist circumference	1.30	4	2	4.4	-0.70	3.0e-01	C6orf106 EVI5 HMGCR PVRL2
Medication: Omeprazole	1.30	1	0	0.0	0.00	1.0e+00	DNAH11
Diabetes diagnosed by doctor	1.30	2	0	0.0	0.00	1.0e+00	APOC1 ATP13A1
Ovarian Cancer	1.29	1	0	0.0	0.00	1.0e+00	CARM1
Mouth/teeth dental problems	1.29	3	0	0.0	0.00	1.0e+00	DOCK7 RASIP1 SDF2
Pack years adult smoking proportion	1.28	1	0	0.0	0.00	1.0e+00	TMED4
Medication for pain relief, constipation, heartburn	1.28	1	0	0.0	0.00	1.0e+00	EFCAB13
Allergy or Eczema	1.26	4	1	2.2	0.82	1.8e-01	ABO ALDH2 C6orf106 PVRL2
Number of live births	1.26	1	0	0.0	0.00	1.0e+00	TMEM258
Mouth/teeth dental problems: Bleeding gums	1.26	1	0	0.0	0.00	1.0e+00	SDF2
BMI	1.25	8	4	8.9	-0.49	2.1e-01	AMIGO1 C6orf106 CEACAM16 EVI5 HMGCR HPR KANK2 SDF2
Chronotype (morning person)	1.24	3	1	2.2	0.00	1.0e+00	ALDH2 AMIGO1 ZNF285
Hayfever, allergic rhinitis or eczema	1.24	2	0	0.0	0.00	1.0e+00	C6orf106 PVRL2
Crohns Disease (2017)	1.23	2	1	2.2	0.00	1.0e+00	RASIP1 TMEM258
Average weekly spirits intake	1.23	1	0	0.0	0.00	1.0e+00	RASIP1
Smoking status: Previous	1.23	1	1	2.2	0.00	1.0e+00	ALDH2
Lung FEV1/FVC ratio	1.22	6	4	8.9	0.14	7.9e-01	C6orf106 EVI5 HP PSRC1 RASIP1 SORT1
Taking other prescription medications	1.22	1	0	0.0	0.00	1.0e+00	ALDH2
Diabetes (self-reported)	1.21	1	0	0.0	0.00	1.0e+00	APOC1
Pack years of smoking	1.21	1	0	0.0	0.00	1.0e+00	TMED4
Body mass index (BMI)	1.20	6	3	6.7	-0.55	2.5e-01	C6orf106 EVI5 GSTM1 HMGCR HPR PVRL2
Back pain experienced in last month	1.18	2	0	0.0	0.00	1.0e+00	APOB C6orf106
Sitting height	1.17	15	4	8.9	-0.16	5.7e-01	ABCG5 ABO AMIGO1 ATP13A1 C6orf106 DCPS EFCAB13 EVI5 FRK HPR KANK2 RASIP1 SPC24 SPTY2D1 TMEM258
Medication: Omeprazole (e.g. Zanprol)	1.15	1	0	0.0	0.00	1.0e+00	DNAH11
Crohns Disease (2012)	1.14	3	0	0.0	0.00	1.0e+00	DOCK7 RASIP1 TMEM258
Leg fat percentage (right)	1.14	4	2	4.4	-0.76	2.4e-01	C6orf106 GSTM1 HMGCR KANK2
Type 2 Diabetes (T2D) (2018)	1.13	1	0	0.0	0.00	1.0e+00	ATP13A1
Trunk fat percentage	1.13	6	3	6.7	-0.49	3.2e-01	C6orf106 FRK GSTM1 HMGCR HPR PVRL2
Leg fat percentage (left)	1.13	5	2	4.4	-0.60	2.9e-01	BCAM C6orf106 GSTM1 HMGCR KANK2
Intelligence (Savage-Jansen 2018)	1.12	5	0	0.0	-0.53	2.8e-01	AMIGO1 DDX56 HPR TMED4 TMEM258
Body fat percentage	1.11	6	3	6.7	-0.49	3.2e-01	BCAM C6orf106 GSTM1 HMGCR HPR PVRL2
Pain experienced in last month	1.11	1	0	0.0	0.00	1.0e+00	ALDH2
Verbal and Numeric Reasoning (VNR)	1.10	2	0	0.0	0.00	1.0e+00	AMIGO1 TMEM258
Impedance of leg (left)	1.09	9	4	8.9	0.38	3.2e-01	ABO AMIGO1 ATP13A1 C6orf106 CARM1 EVI5 HMGCR TMEM167B TMEM50A
Had other major operations	1.09	1	0	0.0	0.00	1.0e+00	ABCG5
Mouth/teeth dental problems: Dentures	1.09	1	1	2.2	0.00	1.0e+00	RASIP1
Arm fat percentage (left)	1.09	6	3	6.7	-0.40	4.4e-01	ABO C6orf106 GSTM1 HMGCR HPR PVRL2
Mood swings	1.09	1	0	0.0	0.00	1.0e+00	AMIGO1
Impedance of arm (right)	1.08	9	3	6.7	0.43	2.5e-01	AMIGO1 C6orf106 EFCAB13 EVI5 GEMIN7 HMGCR KANK2 SDF2 TMEM167B
Impedance of arm (left)	1.08	8	2	4.4	0.01	9.8e-01	ALDH2 AMIGO1 EFCAB13 EVI5 FRK HMGCR KANK2 SDF2
Average weekly champagne plus white wine intake	1.08	1	1	2.2	0.00	1.0e+00	TMEM258
Heel T-Score	1.07	14	6	13.3	-0.58	2.4e-02	ABO ATP13A1 DOCK7 EVI5 HP LDLRAP1 MKRN2 PSRC1 SDF2 SORT1 TMEM258 TMEM50A USP24 ZHX3
Heel bone mineral density (BMD) T-score, automated (right)	1.07	3	0	0.0	0.00	1.0e+00	ABO LDLRAP1 TMEM258
Arm fat percentage (right)	1.06	6	3	6.7	-0.38	4.6e-01	ABO C6orf106 GSTM1 HMGCR HPR PVRL2
Peak expiratory flow (PEF)	1.05	3	1	2.2	0.00	1.0e+00	ABO C6orf106 RASIP1
Headache pain in last month	1.05	1	0	0.0	0.00	1.0e+00	ALDH2
Wheeze or whistling in the chest in last year	1.05	1	0	0.0	0.00	1.0e+00	TMEM258
Ever smoked	1.05	1	0	0.0	0.00	1.0e+00	ALDH2
Impedance of leg (right)	1.01	8	5	11.1	0.38	3.5e-01	ABO AMIGO1 ATP13A1 C6orf106 EVI5 HMGCR TMEM167B TMEM50A
Fed-up feelings	1.01	1	0	0.0	0.00	1.0e+00	ALDH2
Irritability	1.01	3	0	0.0	0.00	1.0e+00	ATP13A1 EFCAB13 TMEM258
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.00	1	0	0.0	0.00	1.0e+00	PVRL2
Reaction Time	0.99	2	1	2.2	0.00	1.0e+00	ALDH2 SMARCA4
Forced expiratory volume in 1-second (FEV1), Best measure	0.98	4	2	4.4	-0.27	7.3e-01	ABO C6orf106 PVRL2 SMARCA4
Heel bone mineral density (BMD) T-score, automated (left)	0.97	2	0	0.0	0.00	1.0e+00	ABO TMEM258
Impedance of whole body	0.97	6	3	6.7	0.89	1.6e-02	AMIGO1 C6orf106 EVI5 FRK HMGCR TMEM167B
Past tobacco smoking	0.96	1	1	2.2	0.00	1.0e+00	ALDH2
Neuroticism	0.95	1	0	0.0	0.00	1.0e+00	AMIGO1
Forced vital capacity (FVC), Best measure	0.93	4	1	2.2	-0.25	7.5e-01	ABO C6orf106 PVRL2 SMARCA4
Systolic blood pressure, automated reading	0.92	2	1	2.2	0.00	1.0e+00	ALDH2 RASIP1
Forced expiratory volume in 1-second (FEV1)	0.92	4	2	4.4	-0.27	7.3e-01	ABO C6orf106 PVRL2 SMARCA4
Qualifications: College or University degree	0.92	3	1	2.2	0.00	1.0e+00	AMIGO1 DNAH11 KLC3
Number of operations (self-reported)	0.92	1	0	0.0	0.00	1.0e+00	ABCG5
Bipolar Disorder or Schizophrenia	0.91	2	0	0.0	0.00	1.0e+00	RASIP1 TMEM258
Irritable Bowel Disease (IBD)	0.91	1	0	0.0	0.00	1.0e+00	TMEM258
Overall health rating	0.91	1	1	2.2	0.00	1.0e+00	C6orf106
Mean time to correctly identify matches	0.90	1	1	2.2	0.00	1.0e+00	ALDH2
Hand grip strength (right)	0.89	2	0	0.0	0.00	1.0e+00	C6orf106 PVRL2
Medication: Bendroflumethiazide	0.87	1	0	0.0	0.00	1.0e+00	RASIP1
Breast Cancer	0.86	2	0	0.0	0.00	1.0e+00	ABO SPTY2D1
Hand grip strength (left)	0.86	1	0	0.0	0.00	1.0e+00	PVRL2
Relative age of first facial hair	0.85	1	1	2.2	0.00	1.0e+00	C6orf106
Forced vital capacity (FVC)	0.84	4	2	4.4	-0.27	7.3e-01	ABO C6orf106 PVRL2 SMARCA4
Schizophrenia (2014)	0.79	1	0	0.0	0.00	1.0e+00	DDX56
Alcohol intake frequency.	0.79	1	1	2.2	0.00	1.0e+00	RASIP1
Age when periods started (menarche)	0.78	2	0	0.0	0.00	1.0e+00	HNF1A RASIP1
Comparative body size at age 10	0.76	1	0	0.0	0.00	1.0e+00	RASIP1
Hair/balding pattern: Pattern 4	0.69	2	1	2.2	0.00	1.0e+00	TMEM258 ZHX3
Lung FVC	0.59	3	1	2.2	0.00	1.0e+00	ABO C6orf106 PVRL2
Hair Pigment	0.17	6	3	6.7	-0.16	7.3e-01	ALDH2 EFCAB13 HS1BP3 MKRN2 SMARCA4 TMEM258
Tanning	0.15	1	0	0.0	0.00	1.0e+00	ALDH2

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Liver	5	0.718	3.6
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	7	0.670	3.5
The Cancer Genome Atlas	Stomach Adenocarcinoma	11	0.691	2.3
GTEx	Whole Blood	8	0.415	2.1
The Cancer Genome Atlas	Colon Adenocarcinoma	8	0.415	2.1
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	7	0.362	2.0
GTEx	Esophagus Mucosa	13	0.402	1.9
ROSMAP	Brain Pre-frontal Cortex	19	0.443	1.9
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	6	0.402	1.9
The Cancer Genome Atlas	Soft Tissue Sarcoma	4	0.404	1.9
GTEx	Muscle Skeletal	9	0.320	1.8
GTEx	Stomach	6	0.423	1.8
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.289	1.8
The Cancer Genome Atlas	Glioblastoma Multiforme	3	0.310	1.8
GTEx	Brain Hippocampus	2	0.392	1.7
GTEx	Pancreas	6	0.376	1.7
GTEx	Pituitary	5	0.455	1.7
GTEx	Skin Sun Exposed Lower leg	13	0.368	1.7
GTEx	Spleen	7	0.507	1.7
NTR	Blood	11	0.461	1.7
YFS	Blood	9	0.197	1.7
CommonMind	Brain Pre-frontal Cortex	23	0.436	1.7
The Cancer Genome Atlas	Brain Lower Grade Glioma	18	0.443	1.7
The Cancer Genome Atlas	Rectum Adenocarcinoma	3	0.462	1.7
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.415	1.7
GTEx	Adrenal Gland	7	0.492	1.6
GTEx	Artery Tibial	12	0.329	1.6
GTEx	Brain Cerebellar Hemisphere	4	0.275	1.6
GTEx	Brain Cortex	2	0.199	1.6
GTEx	Breast Mammary Tissue (Male)	4	0.345	1.6
GTEx	Cells Transformed fibroblasts	21	0.514	1.6
GTEx	Colon Sigmoid	3	0.210	1.6
GTEx	Colon Transverse	6	0.300	1.6
GTEx	Heart Atrial Appendage	2	0.130	1.6
GTEx	Ovary	4	0.451	1.6
GTEx	Skin Not Sun Exposed Suprapubic	5	0.208	1.6
GTEx	Small Intestine Terminal Ileum	2	0.442	1.6
GTEx	Uterus	3	0.541	1.6
The Cancer Genome Atlas	Breast Invasive Carcinoma	13	0.313	1.6
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	13	0.336	1.6
The Cancer Genome Atlas	Lung Adenocarcinoma	12	0.433	1.6
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	6	0.381	1.6
The Cancer Genome Atlas	Prostate Adenocarcinoma	24	0.549	1.6
The Cancer Genome Atlas	Thyroid Carcinoma	15	0.307	1.6
GTEx	Adipose Subcutaneous	8	0.236	1.5
GTEx	Adipose Visceral Omentum	5	0.253	1.5
GTEx	Artery Aorta	7	0.242	1.5
GTEx	Artery Coronary	1	0.087	1.5
GTEx	Brain Cerebellum	4	0.207	1.5
GTEx	Brain Frontal Cortex BA9	1	0.111	1.5
GTEx	Brain Hypothalamus	2	0.349	1.5
GTEx	Brain Putamen basal ganglia	1	0.165	1.5
GTEx	Breast Mammary Tissue	2	0.104	1.5
GTEx	Breast Mammary Tissue (Female)	3	0.190	1.5
GTEx	Cells EBV-transformed lymphocytes	2	0.145	1.5
GTEx	Esophagus Gastroesophageal Junction	1	0.071	1.5
GTEx	Esophagus Muscularis	10	0.318	1.5
GTEx	Nerve Tibial	11	0.261	1.5
GTEx	Prostate	2	0.246	1.5
GTEx	Testis	9	0.292	1.5
GTEx	Thyroid	10	0.258	1.5
GTEx	Vagina	0	0.000	1.5
METSIM	Adipose	16	0.354	1.5
The Cancer Genome Atlas	Esophageal Carcinoma	2	0.308	1.5
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	10	0.389	1.5
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	9	0.380	1.5
GTEx	Brain Caudate basal ganglia	1	0.111	1.4
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.4
GTEx	Heart Left Ventricle	3	0.203	1.4
GTEx	Lung	3	0.107	1.4
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	2	0.129	1.4
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	3	0.239	1.4
The Cancer Genome Atlas	Testicular Germ Cell Tumors	5	0.418	1.4
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.2